Pay in 4 interest-free payments of $10.50 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
TAS-116 triggers enhanced in vivo anti-MM activities
by using three different mouse and human islet in vivo-based models
Epub 2019 May 29
Repeat administration of AS2034178 enhanced insulin sensitivity in an insulin tolerance test and a euglycemic-hyperinsulinemic clamp test
Formula: C20H13FO6
PAI-039 - CAS# 393105-53-8 size:2mg solid TAS-116 triggers enhanced in vivoPAI 039, CAS No. 393105 53 8, is a novel plasminogen activator inhibitor 1 (PAI 1) inhibitor. The pharmacokinetic profile of PAI 039 indicated an oral bioavailability of 43 + 15. 3% and a plasma half life of 6. 2 + 1. 3 h. PAI 039 is an orally active prothrombolytic drug that inhibits PAI 1 and accelerates fibrinolysis while maintaining normal coagulation in a model of coronary occlusion . PAI 039 exerts antithrombotic efficacy in rat models of
US$ 422.50
US$ 437.50
US$ 36.00
US$ 10.80
US$ 25.00
US$ 18.00
US$ 95.00